Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Next Previous
Trial Profile

A First In Human, Open Label, Dose Escalation Phase I Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Clinical Activity Profile Of Single Agent RO7119929 (TLR7 Agonist) Administered Orally To Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RO 7119929 (Primary) ; Tocilizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Liver cancer; Malignant melanoma; Pancreatic ductal carcinoma; Renal cell carcinoma; Skin cancer; Solid tumours; Triple negative breast cancer; Uveal melanoma
  • Focus Adverse reactions; First in man
  • Sponsors Roche

Most Recent Events

  • 19 Apr 2023 Results assessing whether RO7119929 induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients patients, presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 19 Apr 2023 Results (At data cut-off 22 April 2022, n=55 ), presented at the 114th Annual Meeting of the American Association for Cancer Research
  • 27 Jan 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top